You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002
There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
SBC: SA Photonics, Inc. Topic: DTRA19B001
Improving the effectiveness of counter-WMD operations requires improved understanding of weapon-target interaction. Specifically, time-resolved measurements of temperature and composition are required to allow temporal evolution of a detonation fireball. To address this need, SA Photonics will develop MONITOR, a laser-based temperature diagnostic that will enable wide dynamic range temperature mea ...STTR Phase I 2020 Department of DefenseDefense Threat Reduction Agency
SBC: Flow Pharma, Inc. Topic: CBD18A002
Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense